Table 1.
Patients and Tumor Characteristics of the Main and of the Overall Cohorts at Diagnosis and First Relapse
| Overall Cohort | Main Cohort | |
|---|---|---|
| Sex | ||
| Female | 17 (26.6%) | 11 (20.0%) |
| Male | 47 (73.4%) | 44 (80.0%) |
| Age at diagnosis | ||
| Median (interquartile range) | 3.90 (1.95; 8.65) | 4.00 (2.20; 8.70) |
| <3 years old | 40 (62.5%) | 36 (65.5%) |
| ≥3 years old | 24 (37.5%) | 19 (34.5%) |
| Tumor site | ||
| Posterior fossa | 50 (78.1%) | 43 (78.2%) |
| Supratentorial | 14 (21.9%) | 12 (21.8%) |
| Grade | ||
| II | 24 (37.5%) | 19 (34.5%) |
| III | 40 (62.5%) | 36 (65.5%) |
| 1q gaina | ||
| Yes | 10 (26.3%) | 7 (21.9%) |
| No | 28 (73.7%) | 25 (78.1%) |
| Methylation profile scoreb | ||
| ≥80% | 29 (76.3%) | 26 (83.9%) |
| <80% | 9 (23.7%) | 5 (16.1%) |
| Posterior fossa molecular subgroupingb | ||
| A | 26 (92.9%) | 21 (91.3%) |
| B | 1 (3.6%) | 1 (4.3%) |
| <80% profile score | 1 (3.6%) | 1 (4.3%) |
| Supratentorial molecular subgroupingb | ||
| RELA | 5 (55.6%) | 4 (50.0%) |
| <80% profile score | 4 (44.4%) | 4 (50.0%) |
| Shunt | ||
| Yes | 31 (48.4%) | 24 (43.6%) |
| No | 33 (51.6%) | 31 (56.4%) |
| No evidence of disease pre-radiotherapy at first relapse | ||
| Yes | 40 (62.5%) | 36 (65.5%) |
| No | 24 (37.5%) | 19 (34.5%) |
| First relapse | ||
| Local relapse | 41 (64.1%) | 38 (69.1%) |
| Dissemination | 18 (28.1%) | 17 (30.9%) |
| Synchronous relapse | 5 (7.8%) | 0 (0.0%) |
| Metastatic nodule at first relapsec | ||
| Single | 12 (52.2%) | 9 (52.9%) |
| Multiple | 11 (47.8%) | 8 (47.1%) |
| Disease-free interval >5 years | ||
| Yes | 10 (15.6%) | 8 (14.5%) |
| No | 54 (84.4%) | 47 (85.5%) |
| Symptoms at second relapse | ||
| Yes | 19 (29.7%) | 15 (27.3%) |
| No | 45 (70.3%) | 40 (72.7%) |
| Surgery completion at second relapse | ||
| Yes | 32 (50.0%) | 32 (58.2%) |
| No | 17 (26.6%) | 15 (27.3%) |
| Not done | 15 (23.4%) | 8 (14.5%) |
| Site of radiotherapyd | ||
| Local | 31 (59.6%) | 31 (66.0%) |
| CSI | 2 (3.8%) | 1 (2.1%) |
| Other | 19 (36.5%) | 15 (31.9%) |
| Radiotherapy scheduled | ||
| Hypofractionated | 26 (50.0%) | 25 (53.2%) |
| Standard fractionation | 25 (48.1%) | 22 (46.8%) |
| Other | 1 (1.9%) | 0 (0.0%) |
| Chemotherapy done | ||
| Yes | 18 (28.1%) | 16 (29.1%) |
| No | 46 (71.9%) | 39 (70.9%) |
Abbreviations: CSI, craniospinal irradiation; DM, disseminated; LR, local relapse.
a Including patients with methylation profile score ≥0.80 and those with gene fusion analysis.
b On available original samples.
c On DM and LR + DM or DM only patients in overall and main cohort, respectively.
d On patients underwent to radiotherapy.